The CADTH pCODR Advisory Committee (PAC) provides strategic advice for pCODR's ongoing development and management, and provides advice on cancer-specific issues to ensure the pCODR program meets the needs of the provincial/territorial (P/T) governments and cancer agencies.
A Provincial Advisory Group (PAG) is in place to provide advice to the CADTH pCODR Advisory Committee about operational issues, as well as to inform strategic and policy direction. PAG reports to the PAC through its Chair.
The role of the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) is to assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to the provinces and territories to guide their drug funding decisions.
The pan-Canadian Oncology Drug Review (pCODR) relies on the medical expertise of its Clinical Guidance Panels to ensure that the review of each cancer drug draws from the most important, relevant, and current clinical information.
The pan-Canadian Oncology Drug Review (pCODR) relies on the expertise of its Economic Guidance Panels to assess the economic evidence provided when a drug is submitted to pCODR.